PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type

Interventional

Phase

Not applicable

Age range

18 years - 75 years

Sex eligible

All sexes

Healthy volunteers

Accepted

Participants

35 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

This is a study using a self-control approach and is expected to recruit 35 volunteers, including prostate cancer patients, neuroendocrine tumour patients, glioma patients, lung cancer patients, and normal volunteers, to undergo dual-tracer PET/CT imaging and to validate the separation performance and quantitative accuracy of simultaneous dual-tracer imaging in humans.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

• Age: 18 \~75 years old (including boundary values);
• Gender: male or female;
• Normal volunteers: males weighing ≥50kg, females weighing ≥45kg, and body mass index \[BMI = weight (kg)/height 2 (m2)\] within the range of 19.0 \~ 26.0kg/m2 (including borderline values);
• patients with prostate cancer: patients with pathologically-confirmed biochemical relapsed or primary diagnosed prostate cancer with highly suspected systemic metastases on conventional imaging or PSA levels;
• patients with neuroendocrine tumour patients: patients with NET (G2-G3) or NEC confirmed by pathology and highly suspected of having more than 3 metastases by conventional imaging;
• patients with glioma：patients with glioma confirmed by pathology or highly suspected by enhanced MRI and proposed to undergo surgical resection; patients with Lung cancer: patients with lung cancer or suspected recurrent lung cancer.
• Subjects can fully understand and voluntarily participate in this experiment and sign an informed consent form.

Exclusion Criteria:

• Those who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness);
• those with alcohol allergy;
• and those who, in the opinion of the investigator, are unsuitable to undergo or are unable to complete imaging studies such as PET for specific reasons;
• Under 18 years of age or ECOG score \> 2;
• Less than 1 month after completion of radiotherapy and less than 2 months after completion of octreotide treatment in patients with neuroendocrine tumours;
• Women during pregnancy and breastfeeding;
• Practitioners requiring prolonged exposure to radioactive conditions;
• Serious diseases of heart, kidney, lung, vascular, nervous and mental systems, immunodeficiency diseases and hepatitis/cirrhosis;
• Participation in other interventional clinical trials within 1 month prior to screening;
• Presence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable.

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Not applicable

Masking

No masking

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Study team and timeline

Lead sponsor

Xijing Hospital

Study start

Apr 1, 2025 Actual

Primary completion

Mar 1, 2027 Estimated

Study completion

Mar 1, 2027 Estimated

First posted

Apr 6, 2025 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts